BOLT — Q2 2026 Financial Report Analysis

Bolt Biotherapeutics, a clinical-stage cancer drug developer with no products on sale, cut its second-quarter 2026 net loss to $7.7 million from $8.6 million a year earlier. The October 2025 layoff of about half its staff took $3.5 million out of quarterly operating costs. But collaboration revenue all but disappeared, and the company's $18.1 million of cash and investments is only expected to last "into first quarter 2027". The 10-Q again says there is substantial doubt about its ability to continue as a going concern. In accounting language, that means management cannot show it has enough money to keep operating for the next 12 months without raising more.

At a glance

• $18.1 million in cash and marketable securities at June 30, 2026, down from $31.8 million at December 31, 2025. That is about $6.9 million a quarter, and management says it may last only into Q1 2027.
• $8.4 million of operating expenses before the one-off charge, down from $11.0 million a year ago. R&D fell $2.4 million and admin costs fell $1.1 million, mostly from lower headcount.
• $5,000 of revenue, down from $1.8 million. Bolt has stopped work on its Genmab partnership until results from its own lead trial come in.

Key figures

Year-to-date (six months): net loss $15.0 million vs $19.6 million; revenue $31,000 vs $3.0 million.

What the company is betting on

Bolt now relies almost entirely on one experimental drug, BDC-4182. It belongs to a class Bolt calls an "immune-stimulating antibody conjugate" (ISAC): an antibody that homes in on tumour cells, joined to a payload that switches on the patient's own immune system against the tumour. BDC-4182 targets claudin 18.2, a protein found on some stomach cancers. That target is already proven: a plain claudin 18.2 antibody, zolbetuximab, is approved in the US and Japan for advanced stomach cancer. BDC-4182 is in its first human trial, a Phase 1/2 study in gastric and gastroesophageal junction cancer. A Phase 1/2 trial is the early stage that tests safety and dosing and looks for first signs that the drug works. The 10-Q gives no date for trial results.

The trial also holds back the company's second asset. The filing says that because BDC-4182 "is expected to provide insights that may be relevant" to the Genmab collaboration, Bolt "does not expect to perform additional research and development activities" with Genmab until both companies have looked at those results. That is why Genmab revenue went from $1.6 million in Q2 2025 to zero this quarter. If Genmab later takes a candidate forward, the deal could pay Bolt up to $125 million in development milestones and $160 million in sales milestones per drug. Those are payments due only if a drug reaches set stages or sales levels. None of them is counted in the accounts yet, because Bolt says it cannot estimate whether or when they will happen.

Where the cost savings came from

The October 2025 restructuring cut about 20 jobs, roughly 50% of the workforce, at a one-time cost of $1.5 million booked in Q4 2025. Severance payments ran through July 2026. The 10-Q breaks down the year-on-year cost cuts:

• R&D down $2.4 million. Lower personnel costs saved $1.6 million, facilities $0.4 million, lab supplies and contract services $0.2 million, and manufacturing $0.2 million (because of when drug batches were made). Clinical-trial spending rose $0.2 million. Spending on the trial itself is going up while everything around it shrinks.
• Admin (G&A) down $1.1 million. Personnel saved $0.5 million, consulting and professional fees $0.3 million, and marketing and office costs $0.2 million.

What the headline numbers hide

• The smaller loss mostly reflects deep cuts, not improving business. Cost cuts of $3.5 million (before the impairment) were partly offset by $1.8 million of lost collaboration revenue and $0.4 million less interest income. Interest income fell from $0.6 million to $0.2 million because Bolt had less cash to invest and rates were lower. Bolt has already removed half its workforce, so further savings of this size are unlikely.
• A one-off charge, with a lasting effect. The $0.8 million impairment does not involve cash. Impairment means writing down the book value of an asset, here the company's right to use leased office space. It was triggered in June 2026 when a subtenant gave notice that it would end its sublease, using the required 15 months' notice. Bolt books sublease rent (about $0.4 million a quarter) as a reduction of admin costs, so this cost offset ends when the subtenant leaves. Bolt "remains the primary obligor" on the main lease through 2031, which means it still owes the rent. Total lease liabilities are $21.6 million, more than the company's $18.1 million of cash and investments.
• Cash burn is a bit lower than the loss, and both are on the same track. Six-month operating cash outflow was $14.6 million against a $15.0 million net loss. The gap comes from non-cash items: stock compensation, lease expense and the impairment, about $3.1 million in total. These were mostly offset by paying down $1.2 million of payables and accruals and $1.3 million of lease liabilities. Nothing here suggests the cash figures are flattering the result.
• Other income included asset sales. Other income rose to $0.5 million from $50,000. The cash flow statement shows a $0.4 million gain on selling property and equipment in the first half, which looks like selling off lab equipment after the downsizing. That helped the bottom line, but it will not repeat once there is nothing left to sell.
• Loss per share went the other way. The net loss shrank 9.8%, but loss per share widened to $4.57 from $4.46. Weighted-average shares used in the calculation fell to 1.69 million from 1.92 million, even though shares outstanding were 1.93 million at June 30. The 10-Q does not explain the gap. For a company this size, the dollar loss and the cash balance tell you more than the per-share figure. All share figures reflect the 1-for-20 reverse stock split of June 2025.
• Equity is shrinking fast. Stockholders' equity, the accounting value of the company after subtracting all its liabilities, fell to $12.6 million from $26.5 million six months earlier. The accumulated deficit, all the losses since the company was founded, now stands at $475.7 million.

Takeaway: The cuts are working. Operating cash burn is down to about $7 million a quarter from about $11.5 million a year ago. But $18.1 million of cash only covers the company "into first quarter 2027", and Bolt has no revenue to fall back on. Unless it raises new money, signs a partnership or makes a strategic deal, BDC-4182 will not get a chance to show whether it works.

Outlook

Bolt gives no financial guidance beyond the runway statement. Under its current plans, cash, cash equivalents and marketable securities "may be sufficient to fund our operations into first quarter 2027". It expects to meet longer-term needs through "equity or debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements", and warns there is no assurance these will be available "at favorable terms or at all". Financing activities brought in just $25,000 in the first half, from the employee share purchase plan, so no new money has come in yet.

Our read: the next two quarters depend on two things, data from the BDC-4182 trial and financing. Good early data would help Bolt raise money and would also decide whether the Genmab partnership restarts. Without it, the company has little left to cut, and the sublease ending will push admin costs back up by about $0.4 million a quarter once the subtenant leaves. Things to watch in the Q3 10-Q:

• any announcement of BDC-4182 trial data;
• any equity raise or partnering deal, and how much existing shareholders are diluted;
• whether the runway is still "into first quarter 2027" or has been shortened;
• any move toward a sale, merger or wind-down, a common outcome for small biotechs with going-concern warnings.

This is Bolt's first report on our site, so there is no earlier outlook to check against.